Vigifarma - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 30,838 | 213,833 | 35,653 | 132,585 | 151,437 | 658,650 | 64,900 | 35,450 |
| Profit before tax | -81,536 | -41,214 | -20,902 | -79,610 | -20,095 | 192,615 | -20,413 | -6,797 |
| Net profit | -81,536 | -41,214 | -20,902 | -79,610 | -20,095 | 183,902 | -20,413 | -6,797 |
| Equity | -205,846 | -247,060 | -267,962 | -347,572 | -367,667 | -183,765 | -204,178 | -210,974 |
| Liabilities | 516,742 | 683,330 | 804,134 | 903,120 | 949,963 | 847,859 | 879,368 | 714,440 |
| Non-current assets | 192,762 | 187,118 | 177,935 | 175,919 | 168,375 | 164,519 | 162,223 | 162,843 |
| Current assets | 117,865 | 248,800 | 357,933 | 379,227 | 413,647 | 499,476 | 512,852 | 340,501 |
| Total assets | 310,627 | 435,918 | 535,868 | 555,146 | 582,022 | 663,995 | 675,075 | 503,344 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 14,127 | 25,268 | 19,788 |
| Social insurance contributions | - | - | - | - | - | 11,303 | 12,021 | 9,476 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -89.2% | +593.4% | -83.3% | +271.9% | +14.2% | +334.9% | -90.1% | -45.4% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -26.2% | -9.5% | -3.9% | -14.3% | -3.5% | 27.7% | -3.0% | -1.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | - | - | - | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -264.4% | -19.3% | -58.6% | -60.0% | -13.3% | 27.9% | -31.5% | -19.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -264.4% | -19.3% | -58.6% | -60.0% | -13.3% | 29.2% | -31.5% | -19.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | - | - | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 3,558 | 30,188 | 5,942 | 24,477 | 30,287 | 131,730 | 12,980 | 8,682 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Vigifarma - Social security debts
The company had no debts to Sodra
Vigifarma - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Vigifarma, UAB (code 135589965) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €35.5K, down 45.4% year on year and 94.6% compared with 2023. Net loss for the year was €6.8K, an improvement from the €20.4K loss in 2024, but still below the €183.9K net profit recorded in 2023. The 2025 profit margin was -19.2%, reflecting continued pressure on profitability after the sharp decline in sales. The balance sheet remained leveraged: total assets stood at €503.3K, equity was negative at €211.0K, and liabilities amounted to €714.4K. Compared with 2024, assets and liabilities both declined, while equity stayed negative. Operational efficiency was limited, with asset turnover at 0.07x and return on assets at -1.4% in 2025. Revenue per employee was €8.9K and profit per employee was -€1.7K, indicating a low productivity base in the latest financial year.